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Beta blockers are some of the most studied drugs in the pharmacopoeia. They are already widely used in medicine for treating
hypertension, chronic heart failure, tachyarrhythmias, and tremor. Whilst their use in the immediate perioperative patient has
been questioned, the use of esmolol in the patients with established septic shock has been recently reported to have favourable
outcomes. In this paper, we review the role of the adrenergic system in sepsis and the evidence for the use of beta stimulation and
beta blockers from animal models to critically ill patients.
1. Introduction
Although the mortality from septic shock has fallen in
recent years, this has been through improved detection and
earlier antibiotic therapy. Despite intensive research over 20
years, interventions to alter the course of sepsis once the
immune response has initiated have not been found. Recently,
a single centre phase-II study from Italy [1] reported that
beta-adrenergic blockade in patients with septic shock who
continued to have elevated heart rates after standard fluid
resuscitation caused improvements in cardiac performance,
plasma lactate clearance, and a reduction in vasopressor
dependence, with no reported adverse effects. The study
with 77 patients in each group was not powered to examine
survival but nevertheless showed substantial reduction in
short-term mortality (adjusted hazard ratio, 0.39; 95% CI,
0.26 to 0.59;𝑃 < 0.001; twenty-eight-daymortality was 49.4%
in the esmolol group compared with 80.5% in the control
group). This raises the question whether beta blockers could
offer a new way of managing the critically ill patient with
septic shock and if so how its benefits may arise.
In addition to the adrenoceptors found throughout
the cardiovascular system, the adrenergic system is also a
powerful modulator of the immune system [2]. Lymphoid
organs (spleen, thymus, lymph nodes, and bone marrow) are
predominantly innervated by the sympathetic system. With
the exception of T helper type 2 (Th2) cells, the majority
of lymphoid cells express beta-adrenergic receptors on their
surface. The adrenergic system also modulates or regulates
cell death, mitochondrial function, and inflammatory sig-
nalling [3]. Bone marrow production and differentiation of
monocytes is influenced by the adrenergic system [4, 5]
and immune cell apoptosis is at least partly mediated by
catecholamines, via alpha-adrenergic and beta-adrenergic
pathways. Although there has been a great deal of focus on
the cardiovascular benefits of beta blockade in sepsis [6],
the ubiquitous nature of the adrenergic system brings into
question whether there are other mechanisms through which
beta blockers may exert their influence.
2. The (Patho)physiology of the Sympathetic
System during Septic Shock
Interaction between sympathetic nervous and immune sys-
tems is mediated with an effector arm consisting of cat-
echolamines and inflammatory cytokines. In response to
invading pathogens, there is up-regulation of sympathetic
activity enabling the host to mount a rapid and effective
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response. It contributes to the early clinical presentation in
sepsis of flushing, and tachycardia and hypotension caused,
in part, by sympatheticmediated vasodilatation.That is to say
that the cross-talk between the sympathetic system and the
immune system is “physiological” rather than “pathological”
in the first instance. However, there comes a point at which
such an effector system begins to cause injury to the host [7].
The continued elevation of catecholamines observed in some
septic patients becomes unfavourable and for some reason
does not down regulate [8].
The pathophysiology of septic shock includes excessive
sympathetic outflow and high concentrations of plasma
catecholamines leading to vasodilatation followed by vaso-
constriction, vascular hyporeactivity, myocardial depression,
and autonomic dysfunction [7, 8]. The recommended treat-
ment for fluid-unresponsive sepsis-related hypotension is
norepinephrine [9], but this agent has numerous adverse
effects including direct myocardial damage, insulin resis-
tance, thrombogenicity, immunosuppression, and enhanced
bacterial growth [10]. This hypercatecholamine state is in
part also responsible for numerous compensatory metabolic
alterations characteristic of the stress condition, including
the dysregulation of glycaemic control seen after injury
and sepsis [11, 12]. Some of these adverse effects could be
attenuated by beta-adrenergic blockade, since this enables
heart rate control [13] and limits adverse events related to
sympathetic overstimulation [10].
It was noted many years ago that epinephrine enhanced
bacterial infections [14] and decreased the number of bacteria
necessary for a lethal dose in both Clostridia species and
pathogenic aerobic organisms. Catecholamines have been
demonstrated to enhance biofilm formation and stimulate
bacterial growth in Staphylococcus epidermidis [15]. Growth
of Yersinia enterocolitica [16] is enhanced by dopamine and
norepinephrine (but not ephedrine), an effect mediated by
removal of iron from lactoferrin and transferrin by the
catechol moiety and its subsequent acquisition by bacteria
[17]. Escherichia coli O157:H7 and Salmonella enterica also
have enhanced growth with catecholamines.
High plasma catecholamine levels have been noted
in septic animals [18] and humans [8]. Boldt and col-
leagues observed elevated and persistently high plasma cat-
echolamine levels in nonsurvivors in a critically ill patient
population many of whom also received catecholamines
as part of their treatment [19]. In septic shock patients,
arterial norepinephrine levels are significantly associated
with a greater mortality [8]. The extent and duration of
catecholamine therapy and tachycardia are all independently
associated with poor outcomes in critically ill patients [8,
20–22]. Concerns have been raised about the use of cate-
cholamines in the treatment of septic shock [10].
3. Beta Blockers, Sepsis, and the Immune
System: Nonhuman Studies
There has been longstanding interest in beta blockade and
sepsis. As long ago as 1969, Berk et al. [23] used propranolol in
a lipopolysaccharide (LPS) dogmodel and found that the beta
blocker significantly improved survival when it was started 60
minutes after LPS insult. Propranolol also prevented hypoten-
sion and reduced fluid requirements. More recently, selective
beta-1 blocking by esmolol decreased circulating TNF-alpha
and IL-1beta concentrations in septic rats [24], reducing heart
rate and blood pressure. Esmolol also protected LPS treated
pigs from cardiovascular decline in a five hour model [25]
so that in esmolol-treated animals the cardiac index had
decreased by 9% after 3 hours and by only 2% at the end
of the study; in controls the cardiac index had reduced by
14% and by 27%, respectively (𝑃 = 0.870). This was despite
a decrease in heart rate of 20% in the esmolol group and
an increase in heart rate of 22% in controls (𝑃 < 0.001).
Continuous infusion of esmolol initiated after septic insult
improved survival at 5 days in amurinemodel [26] and noted
an increase in the NFkappa B pathway. Similarly, landiolol,
another selective beta-1-blocker, also decreased circulating
levels of TNF-alpha, IL-6, and high mobility group box 1 in
a rat model of endotoxin-induced sepsis [27]. Pretreatment
with atenolol or metoprolol did not alter survival in a cecal
ligation and puncture (CLP) rat model [28] given 2 hrs before
CPL but the median time to death was increased by 33 hrs in
metoprolol-treated rats (𝑃 = 0.03). Metoprolol pretreatment
reduced hepatic expression of proinflammatory cytokines
and lowered plasma IL-6 (both𝑃 < 0.05).Myocardial protein
expression of IL-18 and monocyte chemoattractant protein-
1, key mediators of cardiac dysfunction in sepsis, were also
reduced (𝑃 < 0.05). In another study, atenolol had an anti-
inflammatory effect by increasing IL-10 but had no effect on
TNF-alpha or L-6 concentrations in an ovine model with E.
coli septicaemia [29].
Animal studies of the use of beta-agonists and beta
blockade do not, however, give consistent and predictable
results. Catecholamines have been demonstrated to reduce
isolated human neutrophil function by decreasing free radical
production, [30]. Early use of catecholamines at the same
time as exposure of cells to LPS leads to the downregulation
of synthesis of proinflammatory cytokines such as TNFalpha,
IL-6, and IL-1 [31–33], and upregulates synthesis of anti-
inflammatory cytokines (e.g., IL-10) [32, 33]. Schmitz et al.
[34] demonstrated an increasedmortality inmice treatedwith
propranolol undergoing CLP when beta blocker treatment
was started at the time of surgery. Authors [6] have speculated
that initial fluid resuscitation was impaired and that the non-
selective nature of propranolol reduced the cardioprotection
proffered by beta blockers. This does not entirely explain all
findings and ignores previous animal models [23] reporting
benefit with propranolol.
Lang and colleagues [35] found that beta blockade exac-
erbated a sepsis-induced response in the presence of propra-
nolol. They reported an increase in muscle IL-6 and TNF-
alpha mRNA but did not alter the increment in IL-1alpha.
Furthermore in another study [36], epinephrine infusion did
not increase mortality at 48 hours in a CLP model in mice
but induced alterations of splenocyte apoptosis, splenocyte
proliferation, and IL-2 release. Subsequent treatment with
propranolol augmented the epinephrine-induced increase of
splenocyte apoptosis, did not affect the decrease of splenocyte
proliferation and IL-2 release, augmented the release of IL-6,
and antagonized themobilization of natural killer cells.There
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was also a significant increase in mortality in propranolol
treated animals.
4. Clinical Experience with Beta-Agonism
Studies emerged in the mid-1980s suggesting that patients
treated with dobutamine and who could improve their
cardiovascular performance had a better survival than those
who did not [37, 38]. In particular, Shoemaker’s often quoted
paper [38] suggested that mortality from a protocol-guided
resuscitation regimen could reduce mortality from 23% in
the control group to 4% in surgical patients managed with
a pulmonary artery catheter and the addition of dobutamine
to achieve therapeutic goals that were supranormal values for
cardiac output (>4.5 L/min⋅m2), DO2, (>600mL/min⋅m2),
and VO2 (>170mL/min⋅m2). A subsequent larger resuscita-
tion study [39] also demonstrated improvements in patients
admitted through the emergency department and resusci-
tated according to a CVP based protocol. Rivers’ paper [39]
now forms the basis for fluid resuscitation in the Surviving
Sepsis Campaign Guidelines for the management of severe
sepsis and septic shock [9].
Most intensivists agree that the act of starting dobu-
tamine is not the intervention that improves survival but
it is the ability to achieve supernormal physiological status
that selects out survivors. Shoemaker’s study was followed
shortly after by a study from the UK [40] which failed to
demonstrate improved mortality in patients with established
sepsis. Indeed, their results suggested that aggressive efforts
to increase oxygen consumption could have been detrimental
as the in-hospital mortality was lower in the control group
(34 percent) than in the treatment group (54 percent) (𝑃 =
0.04; 95 percent confidence interval, 0.9 to 39.1 percent). One
important difference, as shall be discussed later, is the timing
of intervention. Hayes’s paper [40] specifically intervened
on patients who had been admitted to ICU and not those
admitted from the emergency department.
There were a number of small studies towards the end of
the last century that were summarised [41] as “Insufficient
evidence exists to support goal-directed therapy with vaso-
pressors and inotropes in the treatment of sepsis syndrome.”
A later analysis by theCochrane collaboration [42] concluded
“Probably the choice of vasopressors in patients with shock
does not influence the outcome. . ..” In the days follow-
ing Shoemaker’s groundbreaking findings, it was therefore
assumed that the use of beta agonism was appropriate for the
management of sepsis despite the fact that Shoemaker studied
patients in the perioperative period. There remain no well-
conducted randomised trials comparing beta-agonism with
placebo.
Although not directly studying sepsis, the Beta Ago-
nist Lung injury Trial 2 (BALTI-2) [43] was a multicentre
randomized controlled trial comparing the selective beta-
2 agonist salbutamol with placebo (0.9% saline) in patients
with Acute Respiratory Distress Syndrome (ARDS). Approx-
imately 25% of the cases included in the trial had ARDS as a
result of sepsis and almost 50% as a result of pneumonia.The
study was stopped early (after recruitment of 326 of a planned
1334 patients) due to increased mortality in the treatment
arm (10.9% (95% CI 1.0% to 20.4%) absolute increase (34.2%
versus 23.3%) in 28-day mortality). 14.2% of patients in the
salbutamol arm (versus 1.2 in the placebo) had the beta
agonist stopped due to tachycardia (HR> 140 bpm)with 8.6%
having treatment withdrawn due to arrhythmias.
A recent study has suggested that vasopressin used
as a norepinephrine-sparing agent may improve outcomes
from less severe septic shock. The overall conclusion of the
Vasopressin versus Norepinephrine Infusion in Patients with
Septic Shock (VASST) [44] study was that there was no
mortality benefit by use of less norepinephrine. However, in
the prospectively defined stratum of less severe septic shock,
the mortality rate was lower in the vasopressin group than
in the norepinephrine group at 28 days (26.5% versus 35.7%,
𝑃 = 0.05); there continues to be a concern that sympathetic
agonism is detrimental to at least some patients with septic
shock.
5. What Is the Clinical Evidence for Beta
Blockers in the Noncardiac Critically Ill
Patient?
The normal myocardial expression of beta-1 and beta-2
adrenoceptors is in the approximate ratio of 3 to 1. In severe
heart failure, this changes to 3 to 2 [45]. Sympathetic stim-
ulation causes post synaptic noradrenergic beta-1 receptor
stimulation whereas beta-2 adrenoceptors, located at extra
junctional as well as post synaptic sites, are stimulated by
circulating catecholamines [46].This relative downregulation
of beta-1 adrenoceptors may well be a protective mechanism
designed to shield the heart from a high sympathetic drive.
Iatrogenically mimicking this with the use of beta blockers
may protect the heart from sympathetic overstimulation in
septic patients. An elevated heart rate is associated with
worse outcomes in septic patients [13]. As the severity of
sepsis increases (SIRS to sepsis to septic shock), there is
reduced heart rate variability and sympathetic activation
worsens [47]. Excessive tachycardia seen in many septic
patients reduces diastolic filling time, increases myocardial
oxygen consumption, and may result in tachycardia induced
cardiomyopathy [48].
Drugs that are antagonists to beta receptors have different
affinities for beta-1 and beta-2 subtypes. Esmolol has a
selectivity of beta-1 to beta-2 ratio of 33 and a half-life (𝑡1/2) =
9.19min [49] with landiolol having a greater affinity for
the beta-1 receptor of beta-1 to beta-2 ratio 255 and 𝑡1/2 =
3.96min [50]. In comparison, propranolol is 74–380 less
selective for beta-1 when comparedwith landiolol and 39–263
when compared with esmolol [51]. Using recombinant cells
expressing beta-1 and beta-2 receptors, Smith and Teitler [52]
determined that bisoprolol was 19 timesmore selective for the
beta-1 receptor and metoprolol 6 times more selective for the
beta-1 receptor when compared with propranolol. It is hardly
surprising then that in combination with the proportions of
beta-1 to beta-2 receptors changing in health and disease,
the response to beta blockade will vary depending upon how
established sepsis is and which drug is selected.
The link between the adrenergic and immune systems
requires further investigation: for example, beta blockade
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has also been shown to reduce proinflammatory cytokines
in heart failure [53], critically ill trauma patients [54], and
appears to have a beneficial effect on the T helper 1/T helper
2 ratio [55]. In a small trial including 55 critically injured
patients at increased risk for heart disease, administration of
metoprolol or esmolol decreased serum interleukin- (IL-) 6
levels [56]. A heart rate above 95 bpm is associatedwithmajor
cardiac events in critically ill patients [22] but this is likely to
be the result of effects on many pathways rather than solely
improving myocardial oxygen utilisation.
Christensen and colleagues [57] performed a retrospec-
tive study in their ICU on 8087 patients over 6 years. In
this case-matched study of 3112 patients (1556 users of beta
blockers and 1556 nonusers), the 30-day mortality was 25.7%
among beta blocker users and 31.4% among nonusers (OR
0.74 (95% CI: 0.63 to 0.87)). The OR was 0.69 (95% CI: 0.54
to 0.88) for surgical ICU patients and 0.71 (95% CI: 0.51 to
0.98) for medical ICU patients. The OR was 0.99 (95% CI:
0.67 to 1.47) among users of nonselective beta blockers, and
0.70 (95%CI: 0.58 to 0.83) amongusers of cardioselective beta
blockers.
Herndon and colleagues successfully used propranolol
to reduce heart rate by 20% in burned septic children and
demonstrated attenuated hypermetabolism and reversal of
muscle-protein catabolism both in the short-term [58] and
over 12 months [59]. A retrospective analysis [60] examining
43 patients either already treated with (21 patients) or com-
mencing beta blockers for other conditions in hospital (such
as hypertension and tachyarrhythmias, 22 patients) suggested
on multivariate analysis that pretreatment with beta blockers
was associated with a significant decrease in fatal outcome
and healing time.
Esmolol has undergone an evaluation of its safety in septic
patients in several small studies; two from Europe [61, 62]
and the authors understand that two case series have reported
the safe use of esmolol in septic patients in China [63, 64].
In his follow-on study, Morelli [1] studied patients admitted
to his hospital with septic shock who had received haemo-
dynamic optimisation of fluid resuscitation and vasopressor
administration to maintain a MAP ≥ 65mmhg, CVP ≥ 8 cm
H
2
0, pulmonary artery wedge pressure (PAWP) ≥ 12mmHg,
and mixed venous saturations (SvO2) > 65%. The primary
outcome was reduction in heart rate within 24 hrs which
was achieved. Surprisingly however, norepinephrine and
resuscitative fluid volume requirements were also reduced
(median area under the curve (AUC) for norepinephrine
of −0.11 𝜇g/kg/min versus −0.01 𝜇g/kg/min, 𝑃 = 0.003.
Median AUC for fluid 3975mL/24 hrs versus 4425mL/24 hr,
𝑃 < 0.001). Stroke volume, systemic vascular resistance,
and left ventricular stroke work indices were all higher in
the esmolol group whilst maintaining MAP ≥ 65mmHg. In
spite of a predictably reduced oxygen delivery (Do2) (median
AUC −100mL/min/m2 versus −32mL/min/m2, 𝑃 < 0.001),
lactate, base excess, and arterial pH were all higher in the
esmolol group. Although not powered to discover amortality
outcome, the authors also reported a substantial reduction in
mortality with a twenty-eight-day mortality of 49.4% in the
esmolol group and 80.5% in the control group.
6. Conclusion
Recent improvement in the mortality from sepsis has largely
come from increased awareness, early management, and
rationalisation of existing supportive measures. Despite
extensive research, the literature is littered with numerous
therapies that brought initial hopes of disease modulation
only to be found not to make patients survive longer and,
in some cases, increased mortality. Beta blockers have been
shown to have immunomodulatory actions in addition to
their cardiovascular effect and a phase II clinical trial [1] has
suggested that beta blockers may have an important role in
the treatment of the patient with septic shock. This study has
raised questions and stimulated interest into why, when, and
in whom beta blockers are beneficial. In particular, it raises
the immediate question: (1) is the effect specifically and only
seen with esmolol or would other beta-1 specific antagonists
also prove beneficial? (2) When should beta blockers be
started? (3) Does the persistence of tachycardia at 24 hours
following resuscitation and presentation with septic shock
select out a group of patients genetically predisposed to do
worse in sepsis and benefit from beta blockade?
Morelli’s findings are tantalising to ICU physicians, some
of whom are already using beta blockade in patients with
established sepsis. Whether their findings are borne out by
larger, multicentre studies remains to be seen.
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